Page 2 - Panacea Biotec
Panacea Biotec hits 52-week high; stock rallies 64% in 4 days
The stock has more-than-doubled in the past one month from the level of Rs 101, as compared to 6.6 per cent gain in Sensex in the same period
 "Panacea Biotec hits 52-week high; stock rallies 64% in 4 days")
Panacea Biotec surges 10% on collaboration with Serum Institute of India
The stock surges 10% to Rs 284 after the company signed two long term agreements with Serum Institute of India and its wholly owned subsidiary, Bilthovan Biologicals BV
 "Panacea Biotec surges 10% on collaboration with Serum Institute of India")
USFDA accepts Panacea Biotec's ANDA for generic cancer drug
This product is a generic version of Abraxane, which is used for treatment of breast cancer, non-small lung cancer and adenocarcinoma of pancreas, it said.
 "USFDA accepts Panacea Biotec's ANDA for generic cancer drug")
Panacea Biotec surges 15% on launch of Prasugrel drug in US market
The stock surged 15% to Rs 276, also its 52-week high on the BSE
 "Panacea Biotec surges 15% on launch of Prasugrel drug in US market")
Panacea Biotec zooms 18% on USFDA approval for migraine drug
The stock surged 18% to Rs 149, also its 52-week high on the NSE in noon deal on back of heavy volumes.
 "Panacea Biotec zooms 18% on USFDA approval for migraine drug")
Panacea Biotec gains on launch of Tetravalent Vaccine Easyfour-TT
The stock surged 10% to Rs 127 on the BSE in intra-day trade in otherwise weak market
 "Panacea Biotec gains on launch of Tetravalent Vaccine Easyfour-TT")
Panacea Biotec gains on EIR from USFDA for Baddi unit
The EIR is for the Baddi unit at Himachal Pradesh for Oncology Parenteral and Oral Solids Dosage formulation facilities
 "Panacea Biotec gains on EIR from USFDA for Baddi unit")
